Clinical/Translational Cancer Immunotherapy

Section Edited by James L. Gulley, MD, PhD and Douglas G. McNeel, MD, PhD

First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations; tumor microenvironment; combination therapies; and cell therapies.

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

Rivka R Colen, Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey, Priyadarshini Mamindla, Pascal O Zinn, Chaan Ng, Raghu Vikram, Spyridon Bakas, Christine B Peterson, Jordi Rodon Ahnert, Vivek Subbiah, Daniel D Karp, Bettzy Stephen, Joud Hajjar, Aung Naing

10.1136/jitc-2020-001752

April 13, 2021

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation

Ryan Michael Reyes, Yilun Deng, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Harshita B Gupta, Alvaro S Padron, Aravind Kancharla, Chenghao Zhang, Myrna Garcia, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia, Robert S Svatek, Tyler J Curiel

10.1136/jitc-2020-002051

April 13, 2021

Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study

Meghan D Lee, Harish Seethapathy, Ian A Strohbehn, Sophia H Zhao, Genevieve M Boland, Riley Fadden, Ryan Sullivan, Kerry L Reynolds, Meghan E Sise

10.1136/jitc-2020-002292

April 13, 2021

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

Giovanni Fucà, Francesca Corti, Margherita Ambrosini, Rossana Intini, Massimiliano Salati, Elisabetta Fenocchio, Paolo Manca, Chiara Manai, Francesca Daniel, Alessandra Raimondi, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Andrea Spallanzani, Virginia Quarà, Carmen Belli, Marta Vaiani, Giuseppe Curigliano, Chiara Cremolini, Filippo De Braud, Maria Di Bartolomeo, Vittorina Zagonel, Sara Lonardi, Filippo Pietrantonio

10.1136/jitc-2021-002501

April 13, 2021

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszus, Christopher B Fountain, George Morris, Noriko Iwamoto, Takashi Shimada, ShuChing Chang, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin, William L Redmond

10.1136/jitc-2021-002371

April 9, 2021

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maio, Olga Nigro, Alessandro Leonetti, Diego L Cortinovis, Joachim GJV Aerts, Giorgia Guaitoli, Fausto Barbieri, Raffaele Giusti, Miriam G Ferrara, Emilio Bria, Ettore D'Argento, Francesco Grossi, Erika Rijavec, Annalisa Guida, Rossana Berardi, Mariangela Torniai, Vincenzo Sforza, Carlo Genova, Francesca Mazzoni, Marina Chiara Garassino, Alessandro De Toma, Diego Signorelli, Alain Gelibter, Marco Siringo, Paolo Marchetti, Marianna Macerelli, Francesca Rastelli, Rita Chiari, Danilo Rocco, Luigi Della Gravara, Alessandro Inno, De Tursi Michele, Antonino Grassadonia, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Marco Filetti, Daniele Santini, Fabrizio Citarella, Marco Russano, Luca Cantini, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Lorenza Landi, Serena Ricciardi, Maria R Migliorino, Francesco Passiglia, Paolo Bironzo, Giulio Metro, Vincenzo Adamo, Alessandro Russo, Gian Paolo Spinelli, Giuseppe L Banna, Alex Friedlaender, Alfredo Addeo, Katia Cannita, Corrado Ficorella, Giampiero Porzio, David J Pinato

10.1136/jitc-2021-002421

April 7, 2021

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma

Yang Liu, Chunmeng Wang, Xiang Li, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Malcolm Brock, Miao Liu, Qian Mei, Jiejie Liu, Jing Nie, Weidong Han

10.1136/jitc-2021-002347

April 5, 2021

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

Zi-Xian Wang, Hao-Xiang Wu, Li Xie, Wu-Hao Lin, Fei Liang, Jin Li, Zhi-Min Yang, Rui-Hua Xu

10.1136/jitc-2020-002114

April 1, 2021

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA

Mark Kalinich, William Murphy, Shannon Wongvibulsin, Vartan Pahalyants, Kun-Hsing Yu, Chenyue Lu, Feicheng Wang, Leyre Zubiri, Vivek Naranbhai, Alexander Gusev, Shawn G Kwatra, Kerry L Reynolds, Yevgeniy R Semenov

10.1136/jitc-2020-001935

March 31, 2021

Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

Justin Ferdinandus, Martin Metzenmacher, Lukas Kessler, Lale Umutlu, Clemens Aigner, Kambartel Otto Karl, Viktor Grünwald, Wilfried Eberhardt, Wolfgang Peter Fendler, Ken Herrmann, Martin Faehling, Daniel Christian Christoph

10.1136/jitc-2020-002262

March 31, 2021